
Release date: 2024-08-06 11:16:35 Article From: Lucius Laos Recommended: 250
Capmatinib inhibits MET phosphorylation by hepatocyte growth factor binding or triggered by MET amplification, as well as MET-mediated phosphorylation of downstream signaling proteins and proliferation and survival of MET-dependent cancer cells.
Capmatinib is a kinase inhibitor targeting MET that blocks MET phosphorylation and activation of key downstream effectors in MET-dependent tumor cell lines. In vitro biochemical and cell experiments, it can effectively inhibit the proliferation and migration of MET-dependent tumor cells, and can induce apoptosis.
MET exon 14 skipping results in protein deletion of regulatory domains, decreasing negative regulation, and leading to increased downstream MET signaling.
Capmatinib inhibits cancer cell growth driven by mutant MET variants lacking clinically attainable exon 14 concentrations and exhibits antitumor activity in a murine tumor xenograft model derived from human lung tumors that results in MET exon 14 skipping or MET amplification.
Lucius Pharmaceuticals Co., Ltd. (Lucius Pharmaceuticals) is a pharmaceutical company founded in 2020 and headquartered in Vientiane, Laos. The company is committed to providing affordable and effective medicines to patients around the world, with the goal of making affordable medical resources accessible to more people.
With modern production facilities and equipment, Lucius Pharmaceuticals has a wide range of products covering anti-tumor, cardiovascular, hematology, diabetes, skin diseases, men's health and anti-aging, with a total of more than 200 generic drugs. The company operates in strict accordance with the International Good Manufacturing Practice (GMP), from raw material procurement to finished product inspection, every step is strictly monitored to ensure the quality and traceability of drugs.
[Warm tips]: During treatment with capmatinib, patients may experience a range of adverse reactions. To mitigate the effects of these reactions, patients should maintain a good state of mind, respond positively, follow their doctor's recommendations, have regular check-ups and assessments, and take appropriate measures to relieve symptoms.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3512025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5522024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3372025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3522025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3932025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3012025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643